益生菌治疗儿童支气管哮喘的临床疗效分析

Analysis of Clinical Effect of Probiotics on Bronchial Asthma in Children

目的研究探讨儿童支气管哮喘患儿实施益生菌治疗的治疗效果,从而有效地为支气管哮喘患儿的治疗提供更多的帮助。方法选择100例该院所收治的支气管哮喘患儿作为研究案例,2017年10月-2018年10月作为该研究的时间范围,采用随机数字表法将其分为实验组与对照组,各为50例。对照组患儿采用常规的抗炎药物、平喘药物以及激素药物进行治疗,实验组患儿在对照组患儿的治疗基础之上加用了益生菌进行治疗。比较两组患儿的治疗效果以及复发率、炎性因子以及肺功能情况、两组患儿家属的治疗满意度情况。结果①治疗后实验组患儿的肺功能指标以及炎性因子指标优于对照组,两组之间差异有统计学意义(P<0.05),其中实验组治疗前的数据分别为(50.35±5.97)ng/L、(285.25±30.58)pg/mL、(96.21±11.25)%、(104.34±10.25)L/min,对照组患者治疗前的数据分别为(50.49±5.15)L/min、(284.61±31.26)L/min、(97.02,±10.29)%、(105.31±11.05)L/min(P>0.05)。实验组患者治疗后的数据分别为(30.24±2.24)ng/L、(157.42±19.26)pg/mL、(97.02±10.46)%、(126.17±8.71)L/min。对照组患者治疗后的数据分别为(41.72±4.28)ng/L、(215.36±23.59)pg/mL、(107.28±10.24)%、(110.24±9.35)L/min(t=16.804、13.453、4.956、8.815,P=0.000、0.000、0.000、0.000、0.000)。②实验组患儿家属的治疗满意率以及治疗满意评分明显高于对照组患儿,两组之间的差异有统计学意义(P<0.05),实验组患者的总满意人数为48例,对照组患者的总满意人数为40例(P<0.05)。③实验组患儿的治疗效果优于对照组患儿,两组患儿的治疗效果差异有统计学意义,实验组的总有效人数为48例,对照组的总有效人数为40例(χ^2=6.061,P=0.014)。④实验组患儿的复发率明显低于对照组患儿,两组患儿之间的数据比较差异有统计学意义(P<0.05),实验组复发4例,对照组复发20例(χ^2=14.035,P=0.000)。结论在该次研究调查当中,可以明确得出结论,益生菌治疗在对儿童支气管哮喘患儿的临床治疗效果良好,值得在临床治疗当中进一步推广应用。

Objective To study the effect of probiotic therapy on children with bronchial asthma,and to provide more help for the treatment of children with bronchial asthma.Methods 100 cases of children with bronchial asthma treated in the hospital were selected as study cases.From October 2017 to October 2018 as the time range of this study,they were divided into experimental group and control group by random number table method.There were 50 cases each.The children in the control group were treated with conventional anti-inflammatory drugs,asthma drugs and hormone drugs.The children in the experimental group were treated with probiotics in addition to the treatment in the control group.The treatment effect,recurrence rate,inflammatory factors and pulmonary function of the two groups of children were compared,and the treatment satisfaction of family members of the two groups of children was compared.Results 1.The lung function indexes and inflammatory factor indexes of children in the experimental group were better than those in the control group after treatment.The differences between the two groups were statistically significant(P<0.05).The data before treatment in the experimental group were(50.35±5.97)ng/L,(285.25±30.58)pg/mL,(96.21±11.25)%,(104.34±10.25)L/min,the data before treatment in the control group were(50.49±5.15)L/min,(284.61±31.26)L/min,(97.02±10.29)%,(105.31±11.05)L/min.The data after treatment in the experimental group were(30.24±2.24)ng/L,(157.42±19.26)pg/mL,(97.02±10.46)%,and(126.17±8.71)L/min(P>0.05).The data of patients in the control group after treatment were(41.72±4.28)ng/L,(215.36±23.59)pg/mL,(107.28±10.24)%,(110.24±9.35)L/min(t=16.804,13.453,4.956,8.815,P=0.000,0.000,0.000,0.000).2.The treatment satisfaction rate and treatment satisfaction score of the children of the experimental group were significantly higher than those of the control group.The difference between the two groups was statistically significant(P<0.05).The total number of satisfied patients in the experimental group was 48,compared with the control group.The total number of satisfied patients was 40(P<0.05).3.The treatment effect of the experimental group was better than that of the control group.The treatment effect of the two groups was different and the difference was statistically significant.The total effective number of the experimental group was 48 and the total effective number of the control group was 40(χ^2=6.061,P=0.014).4.The recurrence rate of children in the experimental group was significantly lower than that in the control group.There was a statistically significant difference in data between the two groups of children(P<0.05).There were 4 cases of recurrence in the experimental group and 20 cases in the control group(χ^2=14.035,P=0.000).Conclusion In this research survey,it can be clearly concluded that probiotic therapy has a good clinical effect on children with bronchial asthma,and it is worth further promotion and application in clinical treatment.